Cargando…
Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology and Endpoint Research Medicare study
BACKGROUND: Dipeptidyl peptidase 4 (DPP4) is a cell surface protein that can act as a tumor suppressor or activator, depending upon the level of expression and interaction with the microenvironment and chemokines. DPP4 inhibitors are used to treat diabetes. METHODS: We conducted this Surveillance Ep...
Autores principales: | Bishnoi, Rohit, Hong, Young‐Rock, Shah, Chintan, Ali, Azka, Skelton, William P., Huo, Jinhai, Dang, Nam H., Dang, Long H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639187/ https://www.ncbi.nlm.nih.gov/pubmed/31124302 http://dx.doi.org/10.1002/cam4.2278 |
Ejemplares similares
-
Impact of DPP4 Inhibitors in Survival of Patients With Prostate, Pancreas, and Breast Cancer
por: Shah, Chintan, et al.
Publicado: (2020) -
A Multi-Center Retrospective Analysis Examining the Effect of Dipeptidyl Peptidase-4 Inhibitors on Progression-Free Survival in Patients With Prostate Cancer
por: Pan, Kelsey, et al.
Publicado: (2021) -
CD26/Dipeptidyl Peptidase IV and Its Multiple Biological Functions
por: Pan, Kelsey, et al.
Publicado: (2021) -
Real‐world experience of carfilzomib‐associated cardiovascular adverse events: SEER‐Medicare data set analysis
por: Bishnoi, Rohit, et al.
Publicado: (2020) -
Current and Emerging Therapy for Malignant Pleural Mesothelioma: Focus on CD26/Dipeptidyl Peptidase IV as a Therapeutic Target
por: Doonan, Bently P., et al.
Publicado: (2017)